Clinical Trial

A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes

Study acronym: YKAA
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how well LY4057996 is tolerated and what side effects may occur in healthy participants and participants with Type 1 and Type 2 Diabetes. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4057996 gets into the bloodstream and how long it takes the body to eliminate it. The study will last 11 weeks for Part A1-A2, 4 weeks for A3-A5, 6 weeks for Part B and 7 weeks for Part C, all approximations, excluding a screening period.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-04-18; most recent amendment 2026-03-09.
Status change: Not Yet Recruiting → Recruiting 2025-05-26
Trial Details
NCT Number NCT06945406
Lead Sponsor Eli Lilly and Company
Conditions Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Enrollment 124 participants
Start Date 2025-05-16
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-11